On September 1, 2021 MAX BioPharma reported that it has been awarded an SBIR Direct-to-Phase II grant from the NIH (NIAMS) titled: "Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion" (R44AR079335-01) (Press release, MAX BioPharma, SEP 1, 2021, View Source [SID1234587151]). With limited options on the market, the medical community is excited about the prospect of a safe, efficacious and less-costly product .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!